Literature DB >> 18637735

Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs.

Michael A Collingwood1, Scott D Rose, Lingyan Huang, Chris Hillier, Mohammad Amarzguioui, Merete T Wiiger, Harris S Soifer, John J Rossi, Mark A Behlke.   

Abstract

Dicer-substrate small interfering RNAs (DsiRNAs) are synthetic RNA duplexes that are processed by Dicer into 21-mer species and show improved potency as triggers of RNA interference, particularly when used at low dose. Chemical modification patterns that are compatible with high potency 21-mer small interfering RNAs have been reported by several groups. However, modification patterns have not been studied for Dicer-substrate duplexes. We therefore synthesized a series of chemically modified 27-mer DsiRNAs and correlated modification patterns with functional potency. Some modification patterns profoundly reduced function although other patterns maintained high potency. Effects of sequence context were observed, where the relative potency of modification patterns varied between sites. A modification pattern involving alternating 2'-O-methyl RNA bases was developed that generally retains high potency when tested in different sites in different genes, evades activation of the innate immune system, and improves stability in serum.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18637735      PMCID: PMC2582043          DOI: 10.1089/oli.2008.0123

Source DB:  PubMed          Journal:  Oligonucleotides        ISSN: 1545-4576


  46 in total

1.  Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity.

Authors:  Bryan A Kraynack; Brenda F Baker
Journal:  RNA       Date:  2005-11-21       Impact factor: 4.942

Review 2.  siRNA and isRNA: two edges of one sword.

Authors:  Martin Schlee; Veit Hornung; Gunther Hartmann
Journal:  Mol Ther       Date:  2006-07-31       Impact factor: 11.454

Review 3.  Design of active small interfering RNAs.

Authors:  Andrew S Peek; Mark A Behlke
Journal:  Curr Opin Mol Ther       Date:  2007-04

4.  Modified 27-nt dsRNAs with dramatically enhanced stability in serum and long-term RNAi activity.

Authors:  Takanori Kubo; Zhivko Zhelev; Hideki Ohba; Rumiana Bakalova
Journal:  Oligonucleotides       Date:  2007

5.  Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo.

Authors:  Adam D Judge; Gurneet Bola; Amy C H Lee; Ian MacLachlan
Journal:  Mol Ther       Date:  2005-12-15       Impact factor: 11.454

6.  Role for a bidentate ribonuclease in the initiation step of RNA interference.

Authors:  E Bernstein; A A Caudy; S M Hammond; G J Hannon
Journal:  Nature       Date:  2001-01-18       Impact factor: 49.962

7.  Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay.

Authors:  I Bièche; C Noguès; V Paradis; M Olivi; P Bedossa; R Lidereau; M Vidaud
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

8.  2'-O-methyl-modified RNAs act as TLR7 antagonists.

Authors:  Marjorie Robbins; Adam Judge; Lisa Liang; Kevin McClintock; Ed Yaworski; Ian MacLachlan
Journal:  Mol Ther       Date:  2007-06-19       Impact factor: 11.454

9.  Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells.

Authors:  Maryam Zamanian-Daryoush; Joao T Marques; Michael P Gantier; Mark A Behlke; Matthias John; Patricia Rayman; James Finke; Bryan R G Williams
Journal:  J Interferon Cytokine Res       Date:  2008-04       Impact factor: 2.607

10.  Improving model predictions for RNA interference activities that use support vector machine regression by combining and filtering features.

Authors:  Andrew S Peek
Journal:  BMC Bioinformatics       Date:  2007-06-06       Impact factor: 3.169

View more
  35 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Comprehensive evaluation of canonical versus Dicer-substrate siRNA in vitro and in vivo.

Authors:  Donald J Foster; Scott Barros; Rick Duncan; Sarfraz Shaikh; William Cantley; Amy Dell; Elena Bulgakova; Jonathan O'Shea; Nate Taneja; Satya Kuchimanchi; Christopher B Sherrill; Akin Akinc; Gregory Hinkle; Amy C Seila White; Bo Pang; Klaus Charisse; Rachel Meyers; Muthiah Manoharan; Sayda M Elbashir
Journal:  RNA       Date:  2012-01-31       Impact factor: 4.942

Review 3.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

4.  Short RNA duplexes guide sequence-dependent cleavage by human Dicer.

Authors:  Lucien Bergeron; Jean-Pierre Perreault; Sherif Abou Elela
Journal:  RNA       Date:  2010-10-25       Impact factor: 4.942

Review 5.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 6.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.

Authors:  Élora Midavaine; Jérôme Côté; Philippe Sarret
Journal:  Cancer Metastasis Rev       Date:  2021-05-11       Impact factor: 9.264

7.  Viral RNAi suppressor reversibly binds siRNA to outcompete Dicer and RISC via multiple turnover.

Authors:  Renata A Rawlings; Vishalakshi Krishnan; Nils G Walter
Journal:  J Mol Biol       Date:  2011-02-24       Impact factor: 5.469

8.  SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation.

Authors:  Shyam Ramachandran; Samantha R Osterhaus; Kalpaj R Parekh; Ashley M Jacobi; Mark A Behlke; Paul B McCray
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

9.  Chitosan/siRNA nanoparticle-mediated TNF-alpha knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model.

Authors:  Kenneth A Howard; Søren R Paludan; Mark A Behlke; Flemming Besenbacher; Bent Deleuran; Jørgen Kjems
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

10.  Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells.

Authors:  Jiehua Zhou; Piotr Swiderski; Haitang Li; Jane Zhang; C Preston Neff; Ramesh Akkina; John J Rossi
Journal:  Nucleic Acids Res       Date:  2009-03-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.